Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Abstract
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
Author
Citations
Altmetric:
Date
2022-07
Type
Article
Subject
Respiratory medicine, Communicable diseases
Collections
Citation
Lancet . 2022 Jul 30;400(10349):359-368
Journal / Source Title
The Lancet
DOI
10.1016/S0140-6736(22)01109-6
PMID
35908569
Publisher
Elsevier
Publisher’s URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333998/